Cartesian Therapeutics, Inc. - Common Stock RNAC 深 滬
已收盤 01-02 16:00:00 美东时间
6.76
-0.450
-6.24%
華盛通- 最 高7.31
- 今 開7.29
- 成交量 21.61万股
- 最 低 6.48
- 昨 收 7.21
- 總市值 1.76亿
- 52周最高 20.12
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 5.98
- 委 比 1.01%
- 總股本 2600.36万
- 歷史最高 840.00
- 量 比 0.83
- 振 幅 11.51%
- 歷史最低 5.98
- 每 手 1
- 風險率 3.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
2025-11-20 10:28
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
BTIG Maintains Buy on Cartesian Therapeutics, Raises Price Target to $44
BTIG analyst Julian Harrison maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the price target from $42 to $44.
2025-11-14 21:11
Cartesian Therapeutics Q3 EPS $(1.38) Misses $(0.84) Estimate, Sales $452.000K Beat $243.500K Estimate
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(0.84) by 63.31 percent. This is a 22.12 percent decrease over losses of $(1.13) per
2025-11-06 20:18
Cartesian Therapeutics Announces Leadership Changes
The latest announcement is out from Cartesian Therapeutics ( ($RNAC) ). On Octo...
2025-10-30 19:27
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics granted inducement stock options to two new employees. The first employee received an option to purchase 50,000 shares at $8.85, vesting 25% on October 27, 2026, with full vesting by October 27, 2029. The second employee received an option for 2,650 shares at $8.20, vesting similarly by October 29, 2029. The company, focused on cell therapies for autoimmune diseases, has assets like Descartes-08 in Phase 3 for myasthenia gr...
2025-10-30 11:05
Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors
Cartesian Therapeutics announced that Carsten Brunn, Ph.D., has been appointed as Chairman of the Board, succeeding Carrie S. Cox, who is focusing on other responsibilities. Descartes-08, the Company's lead CAR-T therapy, is in Phase 3 for myasthenia gravis and Phase 2 for lupus erythematosus, with additional trials planned. The Company also has Descartes-15 in Phase 1 for multiple myeloma. Both Brunn and Cox expressed confidence in the Company's...
2025-10-30 11:00
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
<p>Cartesian Therapeutics announced its management will participate in three investor conferences in September 2025. The events include fireside chats at Cantor Global Healthcare Conference and Morgan Stanley’s Annual Healthcare Conference, and a presentation at the H.C. Wainwright Global Investment Conference. Live webcasts and replays will be available on the company’s website. About Cartesian Therapeutics, the Company is focused on cell therap...
2025-08-28 11:00
Cartesian Therapeutics Q2 EPS $0.50 Compared With $0.54 YoY, Sales Total $298.000K
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $(0.82) by 160.98 percent. This is a 7.41 percent decrease over earnings of $0.54 per share
2025-08-07 19:20
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate
AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR antibody-positive gMG.
2025-07-25 01:08
